ARTICLE | Company News
Zynaxis other research news
July 17, 1995 7:00 AM UTC
The Malvern, Penn., company received a $750,000 Phase II SBIR from the National Heart, Lung, and Blood Institute to couple its Zyn-Linkers to heparin to provide local delivery of heparin and reduce restenosis after angioplasty.
A Phase I trial has shown that Zyn-Linkers enhance binding of heparin to cell membranes, while retaining heparin's anti-clotting activity, ZNXS said. ...